Drugs / DCP-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04739527 | Jun 2021 → Dec 2025 | ovarian cancer | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01373515 | Apr 2011 → Feb 2013 | acute myeloid leukemia | Mendus | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03697707 | Oct 2018 → Mar 2023 | acute myeloid leukemia | Mendus | Unknown | Met primary |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2023-12-11 | Mendus | Results Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023 mendus.com ↗
The longer-term follow up data showed durable treatment responses with survival benefit exceeding historical results expected from the current standard of care in AML maintenance therapy. |
| 2023-11-03 | Mendus | Results Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal mendus.com ↗
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the publication of additional Phase 1 clinical trial data on its lead development program vididencel in the peer-reviewed medical journal HemaSphere. |
| 2023-04-26 | Mendus | Results Mendus announces two upcoming presentations at the 2023 CIMT Annual Meeting mendus.com ↗
Abstract #58, to be featured in an oral presentation, summarizes novel immunomonitoring data from the ADVANCE II trial, a Phase 2 monotherapy trial studying Mendus’ lead program vididencel (DCP-001) as a novel maintenance treatment modality in AML. |
| 2023-04-19 | Mendus | Results Mendus announces positive data from the ALISON trial in ovarian cancer presented at the AACR Annual Meeting 2023 mendus.com ↗
The data presented at AACR demonstrate that vididencel treatment is safe, well-tolerated and induces durable T-cell responses to tumor associated antigens in ovarian cancer patients. |
| 2023-03-15 | Mendus | Results Mendus to present positive interim data from the ALISON trial in ovarian cancer at the AACR Annual Meeting 2023 mendus.com ↗
The ALISON study is progressing well, and the initial read-out with respect to improvements in the patients’ immune cell status and T-cell responses induced by our vaccine are encouraging. |
| 2022-12-12 | Mendus | Results Mendus AB: Mendus presents positive survival data from the ADVANCE II trial evaluating DCP-001 as a maintenance therapy in AML at the American Society of Hematology (ASH) meeting mendus.com ↗
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, presented survival data based on the completed active study period and long-term follow-up to date from the Company’s ADVANCE II clinical trial at the 64th American Society of Hematology Annual Meeting (ASH). |
| 2022-11-03 | Mendus | Results Mendus AB: Mendus to present multiple abstracts at ASH 2022 including an oral presentation of updated AML survival results from the Phase 2 ADVANCE II trial mendus.com ↗
The results to date from ADVANCE II demonstrate that DCP-001 continues to be safe, well-tolerated and has shown increasing evidence of clinical benefit. |
| 2022-10-17 | Mendus | Results Mendus AB: Mendus to report positive clinical and preclinical data in ovarian cancer at the European Society of Gynaecological Oncology 2022 Congress mendus.com ↗
The initial data demonstrates that DCP-001 was safe and well-tolerated, confirming the benign safety profile of DCP-001 observed in multiple completed and ongoing clinical trials. |
| 2022-05-16 | Mendus | Results Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment mendus.com ↗
The analysis demonstrates the therapeutic potential of DCP-001 to control MRD based on the complete read-out of all 20 evaluable patients. |
| 2022-05-03 | Mendus | Results Immunicum AB: Immunicum to Present Preclinical Data Demonstrating Synergy of DCP-001 with Standard Treatments for Acute Myeloid Leukemia mendus.com ↗
The abstract discloses new preclinical data on DCP-001, Immunicum’s lead clinical candidate, in combination with 5’-azacitidine (5-AZA), a hypomethylating agent, and venetoclax (VEN), a BCL2 inhibitor, in a preclinical setting. |
| 2021-12-11 | Mendus | Results Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021 mendus.com ↗
The Phase II data demonstrate the ability of DCP-001 to convert or significantly reduce detectable minimal residual disease (MRD) in acute myeloid leukemia (AML) patients, with fully converted patients demonstrating greater overall survival. |
| 2021-11-22 | Mendus | Results Immunicum Publishes DCP-001 Mechanism of Action in the Journal Cells mendus.com ↗
The publication in the peer-reviewed journal Cells details the interaction between DCP-001 and antigen-presenting cells and the cellular pathways involved. |
| 2021-11-09 | Mendus | Results Immunicum to Present New Research Data at The Society for Immunotherapy of Cancer (SITC) Annual Meeting mendus.com ↗
The study presented by Satwinder Kaur Singh, Ph.D., Director Research at Immunicum, demonstrates that after intradermal injection in a human skin explant model, DCP-001 is taken up by migrating skin dendritic cells and simultaneously leads to the activation of these cells. |
| 2021-06-28 | Mendus | Regulatory Immunicum Receives Advanced Therapy Medicinal Product Classification from the EMA for Cancer Relapse Vaccine Candidate DCP-001 mendus.com ↗
Immunicum AB (publ) today announced that it has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA) for the Company’s lead cancer relapse vaccine candidate, DCP-001. |
| 2021-06-11 | Mendus | Results Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress mendus.com ↗
Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress |
| 2021-05-12 | Mendus | Results Immunicum Announces Presentations at the European Hematology Association (EHA) 2021 Virtual Congress mendus.com ↗
From the interim clinical data published in the abstract today, we are excited to see that DCP-001 induces a range of detectable immune responses in AML patients participating in our ongoing ADVANCE II study |
| 2021-05-03 | Mendus | Results Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting mendus.com ↗
For the abstract covering DCP-001, new preclinical data elucidate the mechanism of action through which DCP-001 can induce specific anti-tumor immunity in patients’ immune cells. |
All press releases naming this drug 19 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03697707 ↗ |
| Modality | Vaccine | “DCP-001 vaccine” NCT01373515 ↗ |